Market Overview:
The global in vitro diagnostics quality control market size is expected to reach USD 1.87 billion by 2032, exhibiting a CAGR of 5.1% during 2024–2032.
In vitro diagnostics are tests that can identify diseases, disorders, or infections. Certain tests are administered in medical facilities or other healthcare settings, while others are designed for patients to perform on their own at home. They consist of medical devices and equipment utilized for conducting tests on samples to help find infections, identify medical conditions, prevent sickness, and supervise drug therapies.
Report Scope:
This comprehensive study provides an accurate overview of the worldwide in vitro diagnostics quality control market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by product & services, technology, manufacturing type, end user, and region in the study, which offers a comprehensive picture of the state of the market.
Drivers and Trends:
- The growing number of chronic illnesses and infectious diseases leads to a higher need for diagnostic testing and monitoring. Chronic disorders are on the rise because of increasing elderly populations, changes in lifestyle, and urban development.
- Improvements in diagnostic technology enhance the precision and quickness of test outcomes. Advances like molecular diagnostics help in detecting genetic and molecular markers more accurately, leading to earlier and more precise diagnoses of diseases like cancer and genetic disorders.
Top Companies:
With so many businesses involved, the market is projected to become more competitive as it continues to grow. Here are the top companies in the in vitro diagnostics quality control market:
Key Companies in Global In Vitro Diagnostics Quality Control Market:
- Abbott Laboratories
- Alpha-Tec Systems
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- CleanNA
- Danaher Corporation
- Fortress Diagnostics
- Grifols, S.A.
- Newland EMEA
- Helena Laboratories Corporation
- Maine Molecular Quality Controls, Inc.
- Microbiologics
- Microbix Biosystems
- Ortho-Clinical Diagnostics
- Qnostics
Country-Wise Insights:
According to regional analysis, in 2023, North America held the largest market share due to the many hospitals, clinical laboratories, and research institutions with advanced healthcare infrastructure; there is a significant demand for quality control products.
Also, during the forecasted period, Asia Pacific is projected to experience the fastest growth because of the rise in IVD manufacturing companies and quality control products, as well as the growing focus on early and accurate diagnostics; the demand for IVD is increasing.
In Vitro Diagnostics Quality Control Market, Product & Service Outlook (Revenue – USD Billion, 2019-2032)
- Quality Control Products
- Serum/Plasma Based Control
- Whole Blood-Based Control
- Urine Based Control
- Other Control
- Data Management Solutions
- Quality Assurance Services
In Vitro Diagnostics Quality Control Market, Technology Outlook (Revenue – USD Billion, 2019-2032)
- Immunochemistry
- Clinical Chemistry
- Molecular Diagnostics
- Microbiology
- Hematology
- Coagulation/Hemostasis
- Other Technologies
In Vitro Diagnostics Quality Control Market, End User Outlook (Revenue – USD Billion, 2019-2032)
- Hospitals
- Clinical Laboratories
- Academic and Research Institutes
- Other End users
In Vitro Diagnostics Quality Control Market, Manufacturer Type Outlook (Revenue – USD Billion, 2019-2032)
- Third-Party Controls
- Independent Controls
- Instrument Specific Controls
- Original Equipment Manufacturer Controls
Recent Developments in Industry:
- September 2023: NeoDx Biotech Labs Launches PCR Diagnostic Kit for Ankylosing Spondylitis
NeoDx Biotech Labs, a startup based in Bengaluru, introduced a real-time PCR-based diagnostic kit for Ankylosing Spondylitis. This innovative kit helps detect Human Leukocyte Antigen B27 (HLA-B27) in whole blood, which is crucial for the early identification and treatment of related inflammatory disorders. The launch significantly improves healthcare testing capabilities, aiding in better disease management and early intervention. - May 2024: Waters Introduces “Waters Connect” Software for In-Vitro Diagnostics
Waters, a leader in analytical instruments, introduced Waters Connect, a new software system designed for in-vitro diagnostics. This platform enhances data integrity, accessibility, security, and compliance, providing researchers with tools to accelerate the development of effective medical tools. The software has the potential to reduce review time by up to 50%, aligning with Waters’ existing TargetLynx software to streamline the diagnostic process and drive innovation in the field of medical diagnostics.
The increasing demand for in vitro diagnostic (IVD) quality control solutions is driven by the rising healthcare needs of aging populations and the surging prevalence of chronic conditions such as diabetes and cardiovascular diseases. Healthcare systems are under pressure to ensure the accuracy and reliability of diagnostic tests, leading to a high focus on quality control in IVD testing. Strict quality control in IVD helps maintain consistency of diagnostic results, minimize errors, and ensure effective treatments.